# Zai Lab Limited (ZLAB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ZLAB
## Company Profile
- Ticker: ZLAB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: China and listed in the U
- Tags: Oncology, Immunology
## Stock Data
- Close: 27 USD
- Market cap: 1926866743.8999999 USD
- Last updated: 2026-09-03
## Business Overview
Zai Lab is a global biopharmaceutical company focused on oncology, infectious disease, and autoimmune disease. Its story combines commercial execution in Asia with a broad development pipeline and international reach.
## Why The Stock Is Moving

As of Sep 3, 2026, ZLAB closed up 1.96% at $27.00. No new same-company headline was identified in the current news window.

## Geographic Base

Zai Lab is headquartered in China and listed in the U.S. market. It sits in global specialty biopharma with a strong oncology footprint.

## Business Model

The company generates value through product commercialization, pipeline progress, and strategic partnerships across major therapeutic areas. Investors watch revenue growth, approvals, and portfolio expansion.

## Landscape Position

Zai Lab occupies a top-tier global biopharma niche. It is more durable than a small-cap biotech name, but pipeline and commercial catalysts still matter a lot.

## Future Catalysts

- Zai Lab’s catalysts are oncology and immunology commercialization, plus any pipeline step that helps the company keep building a broader China-anchored biotech franchise. The stock moves on execution across multiple assets.

## Recent News
- 2023-11-07 21:05 EST — [Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZLAB/zai-lab-announces-third-quarter-2023-financial-results-and-recent-corporate-upda-4fac38c2) — Source: Zai Lab Limited
- 2023-10-26 11:30 EST — [Zai Lab Announces Participation in November Investor Conferences](https://biopharmsignal.com/news/ZLAB/zai-lab-announces-participation-in-november-investor-conferences-d204a165) — Source: Zai Lab Limited
- 2023-10-18 11:30 EST — [Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023](https://biopharmsignal.com/news/ZLAB/zai-lab-to-announce-third-quarter-2023-financial-results-and-recent-corporate-up-9b8e2944) — Source: Zai Lab Limited
- 2023-09-18 11:30 EST — [Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China](https://biopharmsignal.com/news/ZLAB/zai-lab-obtains-breakthrough-therapy-designation-for-efgartigimod-alfa-injection-e313a5db) — Source: Zai Lab Limited
- 2023-08-30 11:30 EST — [Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China](https://biopharmsignal.com/news/ZLAB/zai-lab-announces-breakthrough-therapy-designation-granted-for-repotrectinib-for-7808ddd2) — Source: Zai Lab Limited